CymaBay Therapeutics ( ) - 株価, ニュースと分析Nasdaq:CBAY

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

CBAY 株式概要

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases.

会社概要

CBAY ファンダメンタル分析
スノーフレーク・スコア
評価	2/6
将来の成長	2/6
過去の実績	0/6
財務の健全性	4/6
配当金	0/6

報酬

当社が推定した公正価値より86.9%で取引されている

収益は年間50.87%増加すると予測されています

リスク分析

過去1年間で株主の希薄化が進んだ

現在は利益が出ておらず、今後3年間で利益が出る見込みはない

CymaBay Therapeutics, Inc. 競合他社

Avadel Pharmaceuticals

NasdaqGM:AVDL

US$1.6b

Axsome Therapeutics

NasdaqGM:AXSM

US$4.2b

Nuvation Bio

NYSE:NUVB

US$717.8m

Intra-Cellular Therapies

NasdaqGS:ITCI

US$7.9b

価格と性能

の歴代最高値、変動、値下がりまとめCymaBay Therapeutics
過去の株価
現在の株価	US$32.48
52週高値	US$32.50
52週安値	US$7.26
ベータ	0.32
11ヶ月の変化	0.87%
3ヶ月変化	40.67%
1年変化	262.91%
33年間の変化	607.63%
5年間の変化	147.94%
IPOからの変化	260.89%

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%

Feb 15

Recent updates

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%

Feb 15

Analysts' Revenue Estimates For CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Are Surging Higher

Dec 22

株主還元

	CBAY	US Pharmaceuticals	US 市場
7D	0.03%	2.1%	0.1%
1Y	262.9%	18.8%	24.9%

業界別リターン: CBAY過去 1 年間で18.2 % の収益を上げたUS Pharmaceuticals業界を上回りました。

リターン対市場: CBAY過去 1 年間で21.8 % の収益を上げたUS市場を上回りました。

価格変動

Is CBAY's price volatile compared to industry and market?
CBAY volatility
CBAY Average Weekly Movement	8.2%
Pharmaceuticals Industry Average Movement	10.5%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.1%
10% least volatile stocks in US Market	3.2%

安定した株価: CBAYの株価は過去 3 か月間にわたって変動しています。

時間の経過による変動: CBAYの週次ボラティリティ ( 8% ) は過去 1 年間安定しています。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
1988	101	Sujal Shah	www.cymabay.com

CymaBay Therapeutics, Inc. 基礎のまとめ

CymaBay Therapeutics の収益と売上を時価総額と比較するとどうか。
CBAY 基礎統計学
時価総額	US$3.73b
収益（TTM）	-US$105.37m
売上高(TTM)	US$31.07m

120.0x

P/Sレシオ

-35.4x

PER（株価収益率

CBAY は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
CBAY 損益計算書（TTM）
収益	US$31.07m
売上原価	US$80.80m
売上総利益	-US$49.73m
その他の費用	US$55.64m
収益	-US$105.37m

直近の収益報告

Dec 31, 2023

次回決算日

該当なし

一株当たり利益（EPS）	-0.92
グロス・マージン	-160.03%
純利益率	-339.10%
有利子負債／自己資本比率	37.4%

CBAY の長期的なパフォーマンスは？

過去の実績と比較を見る

CBAY 株式概要

報酬

リスク分析

CymaBay Therapeutics, Inc. 競合他社

NasdaqGM:AVDL

US$1.6b

NasdaqGM:AXSM

US$4.2b

NYSE:NUVB

US$717.8m

NasdaqGS:ITCI

US$7.9b

価格と性能

最新ニュース

CymaBay Therapeutics Files Form 15

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

President exercised options to buy US$4.5m worth of stock.

CymaBay Therapeutics, Inc. Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis

No longer forecast to breakeven

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%

Recent updates

CymaBay Therapeutics Files Form 15

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

President exercised options to buy US$4.5m worth of stock.

CymaBay Therapeutics, Inc. Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis

No longer forecast to breakeven

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%

Price target increased by 8.5% to US$31.07

CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis

CymaBay Therapeutics, Inc. Announces Executive Changes

Forecast to breakeven in 2026

Analysts' Revenue Estimates For CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Are Surging Higher

Cymabay Therapeutics, Inc. and Lewis Stuart, Chief Commercial Officer, Mutually Agrees on Cease to Be an Officer and Employee Effective December 29, 2023

Cymabay Therapeutics, Inc. Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis

President exercised options and sold US$973k worth of stock

President notifies of intention to sell stock

Price target increased by 7.5% to US$24.82

New minor risk - Profitability

CymaBay Therapeutics, Inc. Announces Publication of Two-Year Safety and Efficacy Results of Seladelpar in Patients with Primary Biliary Cholangitis

CymaBay Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

President exercised options and sold US$597k worth of stock

General Counsel notifies of intention to sell stock

CymaBay Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $224.999939 million.

Price target increased by 17% to US$21.27

Insider notifies of intention to sell stock

Consensus revenue estimates increase by 156%

Price target increased by 8.0% to US$17.64

New minor risk - Profitability

CymaBay Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Consensus revenue estimates fall by 15%

Price target increased by 8.5% to US$15.56

Insider notifies of intention to sell stock

Price target increased by 8.2% to US$14.67

New minor risk - Share price stability

Insider notifies of intention to sell stock

General Counsel notifies of intention to sell stock

Consensus revenue estimates fall by 40%

CymaBay Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

CymaBay Therapeutics, Inc. Appoints Harish Shantharam as Chief Financial Officer

Executive Officer notifies of intention to sell stock

Consensus revenue estimates increase by 24%

Price target increased by 11% to US$13.56

Price target increased by 8.1% to US$11.63

CymaBay Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $84.999785 million.

CymaBay Therapeutics (NASDAQ:CBAY) Has Debt But No Earnings; Should You Worry?

CymaBay Therapeutics Presents Additional Analyses from Clinical Studies of Seladelpar for Patients with Primary Biliary Cholangitis

CymaBay Therapeutics, Inc. Announces Executive Changes

CymaBay Therapeutics GAAP EPS of -$0.31 misses by $0.01

CymaBay Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Cymabay Completes Enrollment for the Response Global Phase 3 Study Evaluating Seladelpar for Patients with Primary Biliary Cholangitis

Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?

CymaBay: Long-Term Potential Based On Prior PBC Trial Results

CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from Russell 2000 Dynamic Index

CymaBay Therapeutics, Inc. Presents Positive PBC Data at the International Liver Congress 2022

President recently bought US$100k worth of stock

CymaBay Therapeutics, Inc. Presents New Findings That Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival

Price target decreased to US$10.50

Insufficient new directors

CymaBay Therapeutics, Inc. Appoints Éric Lefebvre to the Audit Committee and the Nominating and Corporate Governance Committee of the Board

Is CymaBay Therapeutics (NASDAQ:CBAY) Using Debt In A Risky Way?